Products
-
- BBB DamageCell Death and ApoptosisNeuroinflammationNeuronal Damage and RepairOxidative StressVascular Mechanisms
- 3D BBB Models
- Organ-on-a-Chip BBB ModelsTranswell Models3D BBB Models Culture Substrate
- 3D HydrogelsCollagensAnmial BBB ModelsCell Lines for BBB Modeling
- Immortalized CellsPrimary CellsStem Cells
Human NDP ELISA Kit (AC3133)
Cat.#: ASET-1722
Specifications
Description Human NDP ELISA Kit, a 90-minute assay kit, allows for the in vitro quantitative determination of human NDP concentrations in serum, plasma, and other biological fluids. Size 96T Sample Type Serum, plasma or other biological fluids. Reactivity Human Unit 1 kit Packaging Kit of pre-coated 96 well microplates (12 x 8 well strips) Detection Type Colorimetric Assay Type Quantitative Sensitivity 0.056 ng/ml Precision Intra-assay CV: < 8%
Inter-assay CV: < 10%Product Range 1.5-24 ng/mL Assay Time ~90 min Storage Store the unopened kit at +4°C. Shipping Wet ice Citation Guidance If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. Related Products
Cat.# Name Assay Type Price ASET-1886 Human GDF7 ELISA Kit (AC3297) Quantitative inquiry ASET-1345 Mouse Prealbumin ELISA Kit (AC2756) Quantitative inquiry ASET-2084 Mouse PEDF ELISA Kit (AC3495) Quantitative inquiry ASET-1581 Human PLXNA3 ELISA Kit (AC2992) Quantitative inquiry ASET-1156 Human PER2 ELISA Kit (AC2567) Quantitative inquiry ASET-2455 Mouse QPRT ELISA Kit (AC3866) Quantitative inquiry ASET-2209 Mouse TMPRSS2 ELISA Kit (AC3620) Quantitative inquiry ASET-1935 Human CXCR4 ELISA Kit (AC3346) Quantitative inquiry ASET-1523 Human Glicentin ELISA Kit (AC2934) Quantitative inquiry ASET-1974 Rat p75 NGF Receptor ELISA Kit (AC3385) Quantitative inquiry All of our products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.
0Inquiry Basket